New Molecular Targets for Antidepressant Drugs

Pharmaceuticals

Erich Gulbins¹  Johannes Kornhuber² 

[1] Department of Molecular Biology, University of Duisburg-Essen, 45117 Essen, Germany;Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany;

关键词: acid sphingomyelinase;    ceramide;    sphingomyelin;    FIASMA;    antidepressant drug;    lysosome;   

DOI  :  10.3390/ph14090894

来源: DOAJ

【 摘 要 】

Major depressive disorder (MDD) is a common and severe mental disorder that is usually recurrent and has a high risk of suicide. This disorder manifests not only with psychological symptoms but also multiple changes throughout the body, including increased risks of obesity, diabetes, and cardiovascular disease. Peripheral markers of oxidative stress and inflammation are elevated. MDD is therefore best described as a multisystem whole-body disease. Pharmacological treatment with antidepressants usually requires several weeks before the desired effects manifest. Previous theories of depression, such as the monoamine or neurogenesis hypotheses, do not explain these characteristics well. In recent years, new mechanisms of action have been discovered for long-standing antidepressants that also shed new light on depression, including the sphingolipid system and the receptor for brain-derived neurotrophic factor (BDNF).

【 授权许可】

Unknown